The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients will continue.

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that, while often latent in the general population, can become reactivated in individuals with compromised immune systems. Inflammatory bowel disease ...

The study, titled “ Strategic Help with Immunoglobulin to Enhance protection against Late Disease (CMV) ” or SHIELD, is a prospective, randomized, controlled multicenter investigator-initiated study ...

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a large Phase 3 trial, prompting the company to end its congenital CMV program.

A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the presentation of findings from a systematic literature review and ...

A VIRAL INFECTION THAT IMPACTS UP TO 5% OF BABIES. AND WE’RE GOING TO TALK ABOUT IT. LET’S TALK ABOUT IT WITH DOCTOR KRISTEN MOFFITT, AN INFECTIOUS DISEASE SPECIALIST AT BOSTON CHILDREN’S HOSPITAL.

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.

Credit: Getty Images. Prevymis is a CMV DNA terminase complex inhibitor. The Food and Drug Administration (FDA) has approved Prevymis ® (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in ...

VANCOUVER, British Columbia—Cytomegalovirus (CMV) infection in kidney or kidney/pancreas transplant recipients occurs more frequently when alemtuzumab is used for induction instead of antithymocyte ...